Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zura BioZURA -1.07%22 EV-to-EBIT is -3.54 as of Aug. 15, 2026. GuruFocus rates ZURA with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 368 Biotechnology companies, Zura Bio ranks worse than 271738.86% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zura Bio's Enterprise Value is $328.64 Mil.
Zura Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-92.75 Mil. Therefore, Zura Bio's EV-to-EBIT for today is -3.54.
The historical rank and industry rank for Zura Bio's EV-to-EBIT or its related term are showing as below:
ZURA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -3.63 Med: 0 Max: 0
Current: -3.54
ZURA's EV-to-EBIT is ranked worse than 100% of 368
companies
in the Biotechnology industry
Industry Median: 15.71
vs ZURA: -3.54
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zura Bio's Enterprise Value for the quarter that ended in Jun. 2026 was $357.86 Mil.
Zura Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zura Bio EV-to-EBIT Related Terms
Zura Bio EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zura Bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zura Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zura Bio EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zura Bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zura Bio's EV-to-EBIT falls into.
Zura Bio's current Enterprise Value is $328.64 Mil.
Zura Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zura Bio (ZURA) has a EV-to-EBIT of -3.54 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zura Bio and its competitors. According to the industry distribution chart, Zura Bio ranks #999999 out of 368 companies in the Biotechnology industry.
Is Zura Bio's EV-to-EBIT too high?
Zura Bio's current EV-to-EBIT is -3.54. Based on the distribution chart, Zura Bio ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zura Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's EV-to-EBIT compare to ASMB and ARTV?
According to the Biotechnology industry distribution chart, Zura Bio ranks #999999 out of 368 companies for EV-to-EBIT. This places Zura Bio in the lower half of its industry. The industry median EV-to-EBIT is 15.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.71, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zura Bio and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zura Bio's current EV-to-EBIT is -3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (ZURA) has a current EV-to-EBIT of -3.54. The current EV-to-EBIT is -3.54. Zura Bio's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zura Bio (ZURA), the current EV-to-EBIT is -3.54 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
22GF Score
Get the complete analysis for ZURA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZURA has been successfully added to your 
